Every 10-Q that Innoviva, Inc. (INVA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow INVA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full INVA filings page.
Innoviva, Inc. reported Q2 2026 total revenue of $119.6 million, up from $100.3 million a year earlier, with income from operations of $50.9 million. The quarter nevertheless showed a net loss of $83.4 million, mainly from a $131.8 million unrealized loss on Armata equity holdings and $29.2 million losses on other investments.
For the first six months of 2026, total revenue reached $217.6 million and net income was $103.2 million, compared with $188.9 million in revenue and $17.1 million in net income in 2025, helped by earlier-period fair‑value gains and higher net product sales, particularly GIAPREZA and XACDURO.
Cash and cash equivalents were $570.4 million as of June 30, 2026, against $258.5 million of long‑term convertible notes, and stockholders’ equity was $1.23 billion. The company repurchased 2.37 million shares in the first half of 2026 for approximately $51.8 million.
Innoviva, Inc. reported strong first-quarter 2026 results, with total revenue of $97.994 million, up from $88.632 million a year earlier, driven mainly by higher net product sales. Royalty revenue was $55.167 million, slightly below the prior year, while product sales rose to $41.371 million from $30.279 million, helped by XACDURO and the launch of ZEVTERA.
Net income swung to a profit of $186.595 million from a loss of $46.584 million, largely due to favorable fair value movements in equity method and other investments totaling over $191 million. Operating income from the underlying business was $38.154 million, modestly below the prior-year level as selling, general and administrative expenses increased. Cash and cash equivalents grew to $603.085 million, even after repurchasing about $20.4 million of common stock during the quarter.
Innoviva, Inc. reported stronger Q3 2025 results. Total revenue for the three months ended September 30, 2025 was $107.8 million, up from $89.5 million a year ago, driven by $59.9 million in royalty revenue and $47.3 million in net product sales. Net income rose to $89.9 million (diluted EPS $1.08) from $1.2 million (diluted EPS $0.02) in Q3 2024, aided by gains in the fair values of investments.
Year-to-date through Q3 2025, revenue reached $296.7 million with net income of $107.0 million. Cash and cash equivalents were $476.5 million as of September 30, 2025, supported by $142.4 million in operating cash flow for the nine-month period. The company eliminated its current balance on the 2025 convertible notes through conversions totaling $192.5 million to common stock, while long-term debt stood at $257.4 million. Common shares outstanding were 74,769,062 as of October 31, 2025.